药物代谢酶CYP2C19基因多态性与多种药物的代谢和治疗效果有关，检测CYP2C19基因型对于临床精准用药至关重要。目前CYP2C19基因型检测方法存在不易判读、不适合微型化的缺点，建立一种直观判读、特异性强、易于微型化的CYP2C19基因型检测方法具有重要的临床意义。申请者前期建立了一种基于连接酶链式反应（LCR）和多聚辣根过氧化物酶信号放大体系的电化学传感器，能特异性区分CYP2C19*2的纯合野生型和突变型。本项目在此基础上，拟解决前期研究过程中CYP2C19*2杂合型和纯合型不易区分的问题，通过电化学生物传感方法，将LCR核酸扩增技术、Lambda核酸外切酶高效切割dsDNA的特性、电活性指示剂特征峰性质有机结合，构建一种灵敏、准确、直观、稳定的倒立型DNA纳米结构电化学传感器，实现临床样品中CYP2C19基因型的同时检测，为临床精准“药”疗提供实验室依据和科学指导。

Gene polymorphism of drug metabolizing enzyme CYP2C19 is related to the metabolism and therapeutic efficacy of various drugs, such as clopidogrel and proton pump inhibitors. Genotype detection of CYP2C19 is crucial for clinical precise medication. At present, CYP2C19 genotype detection method has some shortcomings, such as difficult to interpret and unsuitable for miniaturization, It is of great significance to establish a CYP2C19 genotype detection method with characteristic of intuitive interpretation, specificity and easily miniaturized. In previous study, we established an electrochemical sensor to specifically distinguish homozygous wild type and mutant type CYP2C19*2 based on Ligase chain reaction (LCR) and Polymeric horseradish peroxidase (Poly-HRP) signal amplification system. On this basis, this project aims to solve the problem that CYP2C19*2 heterozygous and homozygous types are not easy to distinguish in the previous research. Through electrochemical biosensor method, a sensitive, accurate, intuitive and stable inverted DNA nanostructure electrochemical sensor is constructed by organic combination of LCR nucleic acid amplification technology, the characteristics of lambda-Exo cleavage dsDNA and the properties of characteristic peaks of electroactive indicators to simultaneous detection of CYP2C19 genotype in clinical complex samples, and provide laboratory basis and scientific guidance for clinical precise "drug" therapy.